PAQR4 was discovered to disrupt the interaction between Nrf2 and Keap1 in non-small-cell lung cancer (NSCLC), preventing Nrf2 protein degradation and thereby decreasing the sensitivity of malignant cells to chemotherapy [42]. Here, PAQR4 is linked to non-small cell lung carcinoma.